A year after Tysabri was reintroduced for multiple sclerosis [1], its manufacturers say that 14,000 patients are now taking the drug. Tysabri, once viewed as a major breakthrough for MS, was pulled after the drug was linked to a risk of PML, a viral infection of the brain. Elan and Biogen Idec make the drug.
- read the report [2] from Finfacts
Related Articles:
FDA allows Tysabri back on market. Report [1]
FDA allows limited trial of Tysabri. Report [3]
Tysabri may spur better risk/reward evaluation. Report [4]
Elan hammered on reported case of PML. Report [5]
Links:
[1] http://www.fiercebiotech.com/story/fda-allows-tysabri-back-on-market/2006-06-06
[2] http://www.finfacts.com/irelandbusinessnews/publish/article_1010660.shtml
[3] http://www.fiercebiotech.com/story/fda-allows-limited-trial-of-tysabri/2006-02-16
[4] http://www.fiercebiotech.com/story/tysabri-may-spur-better-risk-reward-evaluation/2006-03-10
[5] http://www.fiercebiotech.com/story/elan-hammered-on-reported-case-of-pml/2005-06-02